{"id":"https://openalex.org/W4684676","doi":null,"title":"Curdlan sulfate (CRDS) in a 21-day intravenous tolerance study in human immunodeficiency virus (HIV) and cytomegalovirus (CMV) infected patients: indication of anti-CMV activity with low toxicity.","display_name":"Curdlan sulfate (CRDS) in a 21-day intravenous tolerance study in human immunodeficiency virus (HIV) and cytomegalovirus (CMV) infected patients: indication of anti-CMV activity with low toxicity.","publication_year":1997,"publication_date":"1997-01-01","ids":{"openalex":"https://openalex.org/W4684676","mag":"4684676","pmid":"https://pubmed.ncbi.nlm.nih.gov/9249617"},"language":"en","primary_location":{"id":"pmid:9249617","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9249617","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of medicine","raw_type":"Clinical Trial"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"M Gordon","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M Gordon","raw_affiliation_strings":["AJI Pharma USA, Inc., Teaneck, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AJI Pharma USA, Inc., Teaneck, NJ, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063704053","display_name":"Steven G. Deeks","orcid":"https://orcid.org/0000-0001-6371-747X","observed_orcids":["https://orcid.org/0000-0001-6371-747X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S Deeks","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055024640","display_name":"C De Marzo","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C De Marzo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110397823","display_name":"J Goodgame","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J Goodgame","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009723108","display_name":"Mario Guralnik","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M Guralnik","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082185009","display_name":"Wiegand Lang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W Lang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"T Mimura","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T Mimura","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"D Pearce","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D Pearce","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":null,"display_name":"Y Kaneko","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Y Kaneko","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.8498,"has_fulltext":false,"cited_by_count":27,"citation_normalized_percentile":{"value":0.73255233,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"28","issue":"1-2","first_page":"108","last_page":"28"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.4343000054359436,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.4343000054359436,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.39890000224113464,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10981","display_name":"Cytomegalovirus and herpesvirus research","score":0.10490000247955322,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sulfated-polysaccharides","display_name":"sulfated polysaccharides","score":0.8949999809265137},{"id":"https://openalex.org/keywords/cytomegalovirus-infection","display_name":"cytomegalovirus infection","score":0.8700000047683716},{"id":"https://openalex.org/keywords/hiv-infection","display_name":"HIV infection","score":0.9750000238418579},{"id":"https://openalex.org/keywords/intravenous-administration","display_name":"intravenous administration","score":0.5329999923706055},{"id":"https://openalex.org/keywords/drug-tolerance","display_name":"drug tolerance","score":0.6050000190734863},{"id":"https://openalex.org/keywords/cd4-count","display_name":"CD4 count","score":0.8799999952316284},{"id":"https://openalex.org/keywords/reverse-transcriptase-inhibitors","display_name":"reverse transcriptase inhibitors","score":0.8240000009536743},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.4569999873638153},{"id":"https://openalex.org/keywords/platelet-count","display_name":"platelet count","score":0.5659999847412109},{"id":"https://openalex.org/keywords/p24-antigen","display_name":"p24 antigen","score":0.843999981880188},{"id":"https://openalex.org/keywords/antiviral-therapy","display_name":"antiviral therapy","score":0.652999997138977},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.5640000104904175},{"id":"https://openalex.org/keywords/viral-load","display_name":"viral load","score":0.4230000078678131},{"id":"https://openalex.org/keywords/immunomodulation","display_name":"immunomodulation","score":0.515999972820282}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9188083410263062},{"id":"https://openalex.org/C2780026642","wikidata":"https://www.wikidata.org/wiki/Q40924","display_name":"Urine","level":2,"score":0.5351190567016602},{"id":"https://openalex.org/C2777732132","wikidata":"https://www.wikidata.org/wiki/Q6946","display_name":"Cytomegalovirus","level":5,"score":0.5090710520744324},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.4395417869091034},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.43951335549354553},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.41037434339523315},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4088095426559448},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3910600244998932},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.3412756323814392},{"id":"https://openalex.org/C2780727368","wikidata":"https://www.wikidata.org/wiki/Q1928978","display_name":"Viral disease","level":3,"score":0.21070319414138794},{"id":"https://openalex.org/C2776409557","wikidata":"https://www.wikidata.org/wiki/Q149348","display_name":"Herpesviridae","level":4,"score":0.10422408580780029}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D003586","descriptor_name":"Cytomegalovirus Infections","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":true},{"descriptor_ui":"D003586","descriptor_name":"Cytomegalovirus Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003586","descriptor_name":"Cytomegalovirus Infections","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D004361","descriptor_name":"Drug Tolerance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005936","descriptor_name":"Glucans","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D005936","descriptor_name":"Glucans","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D005936","descriptor_name":"Glucans","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007262","descriptor_name":"Infusions, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017088","descriptor_name":"AIDS-Related Opportunistic Infections","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":true},{"descriptor_ui":"D017088","descriptor_name":"AIDS-Related Opportunistic Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D017088","descriptor_name":"AIDS-Related Opportunistic Infections","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D018791","descriptor_name":"CD4 Lymphocyte Count","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047071","descriptor_name":"beta-Glucans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:9249617","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9249617","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of medicine","raw_type":"Clinical Trial"},{"id":"mag:4684676","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9249617","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2466686268","https://openalex.org/W2425892144","https://openalex.org/W2000692298","https://openalex.org/W2051593410","https://openalex.org/W2328424493","https://openalex.org/W2158179663","https://openalex.org/W2325855101","https://openalex.org/W1988157903","https://openalex.org/W3119701429","https://openalex.org/W2108385781"],"abstract_inverted_index":{"This":[0],"study":[1,189,217,312],"evaluated":[2],"tolerance":[3],"(and":[4],"possible":[5],"efficacy)":[6],"for":[7,123,150,172,177,226,306,351],"21":[8,124,187,222,242,307],"days":[9,308],"of":[10,17,45,73,88,92,115,131,165,182,231,241,260,266,332,344,362,383,392],"i.v.":[11,118],"administration":[12],"at":[13,228,238],"three":[14],"dose":[15,128,294],"levels":[16,40,289],"curdlan":[18],"sulfate":[19,211],"(CRDS)":[20],"(a":[21],"semisynthetic":[22],"sulfated":[23,75],"polysaccharide),":[24],"administered":[25],"over":[26,119,257],"30":[27],"minutes,":[28],"in":[29,77,156,162,180,185,200,204,215,268,287,291,309,323,375,394],"HIV":[30,78,93,301,324,353,371],"and":[31,63,86,111,141,159,167,176,192,202,295,341,372,387],"CMV":[32,99,173,227,236,253,322,393],"(in":[33],"some":[34,157],"cases)":[35],"infected":[36,325],"individuals":[37],"with":[38,51,98,104,138,209,218,317,328,377],"CD4":[39,151,288],"<":[41,276],"500":[42],"cells/mm3.":[43],"Half":[44],"the":[46,60,65,132,221,229,232,239,292,296,310,359,381,389],"subjects":[47],"were":[48,57,101,135,143,148,169,212,235,303],"previously":[49,207],"treated":[50,102,137],"reverse":[52],"transcriptase":[53],"inhibitors":[54],"(RTI)":[55],"(which":[56],"continued":[58],"during":[59],"CRDS":[61,116,184,267,298,318,337,400],"administration)":[62],"half":[64,130,142],"patients":[66,94,133,223,302],"had":[67,79,272],"no":[68,145],"prior":[69],"RTI":[70,140],"treatment.":[71],"Evaluation":[72],"other":[74,378],"polysaccharides":[76],"been":[80],"discontinued":[81],"due":[82],"to":[83,255,366],"side":[84,196],"effects":[85],"lack":[87,343],"activity.":[89],"Three":[90],"groups":[91],"(also":[95],"including":[96],"subsets":[97,181],"infection)":[100],"separately":[103],"50":[105],"mg/70":[106,109,113],"Kg,":[107],"100":[108],"Kg":[110,114],"200":[112],"infused":[117],"thirty":[120],"minutes":[121],"daily":[122,330,356],"days.":[125,243],"In":[126,220,244],"each":[127],"group,":[129,249],"selected":[134],"being":[136],"a":[139,258,273],"on":[144,279,300,399],"RTI.":[146],"Patients":[147],"monitored":[149],"cell":[152],"levels,":[153],"viral":[154],"load":[155],"cases,":[158],"safety":[160],"parameters":[161],"blood.":[163],"Samples":[164],"urine":[166],"semen":[168],"additionally":[170],"taken":[171],"by":[174],"culture":[175],"PCR":[178],"assay":[179],"participants.":[183],"this":[186,216,269,333],"day":[188],"was":[190,338],"well-tolerated":[191],"produced":[193],"few":[194],"reportable":[195],"effects.":[197],"Systematic":[198],"decreases":[199],"platelets":[201],"increases":[203,286],"p24":[205],"antigen":[206],"seen":[208,290,305],"dextran":[210],"not":[213],"observed":[214],"CRDS.":[219],"testing":[224],"positive":[225,254],"start":[230],"study,":[233,270],"12":[234],"negative":[237,256],"end":[240],"an":[245,348],"untreated":[246],"historical":[247,281],"control":[248],"0/36":[250],"went":[251],"from":[252],"period":[259],"13-15":[261],"years.":[262],"The":[263,283],"anti-CMV":[264,385],"activity":[265],"therefore,":[271],"p":[274],"value":[275],"0.001,":[277],"based":[278],"these":[280],"controls.":[282],"marked":[284],"temporary":[285],"single":[293],"seven-day":[297],"studies":[299,398],"also":[304],"current":[311],"(p":[313],"=":[314],"0.0001).":[315],"Treatment":[316],"seems":[319],"promising":[320],"against":[321,369],"patients,":[326],"even":[327],"once":[329],"dosing":[331],"two-hour":[334],"half-life":[335],"drug.":[336],"well":[339],"tolerated":[340],"its":[342],"toxicity":[345,382],"makes":[346],"it":[347],"attractive":[349],"candidate":[350],"CMV-infected":[352],"patients.":[354],"Multiple":[355],"dosing,":[357],"or":[358],"continuous":[360],"infusion":[361],"CRDS,":[363],"could":[364],"lead":[365],"increased":[367],"effectiveness":[368],"both":[370],"CMV,":[373],"especially":[374],"combination":[376],"agents.":[379],"Given":[380],"existing":[384],"agents,":[386],"considering":[388],"emerging":[390],"importance":[391],"atherosclerotic":[395],"disease,":[396],"further":[397],"are":[401],"warranted.":[402]},"counts_by_year":[{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":2},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}